TY  - JOUR
AU  - Irving, Glen R. B.
AU  - Lobo, Dileep N.
PY  - 2016
TI  - Pancreatic ductal adenocarcinoma—a new hope?
JF  - Translational Cancer Research; Vol 5, Supplement 2 (August 22, 2016): Translational Cancer Research
Y2  - 2016
KW  - 
N2  - Pancreatic ductal adenocarcinoma (PDAC) is typically an advanced and aggressive disease and improving outcomes for patients with this cancer remains a significant challenge. Few patients present with resectable disease, and recurrence rates after surgery remain high (70–80%). Modern chemotherapy (CMT) and radiotherapy (RT) regimens have made small improvements to survival and many of these treatments confer little benefit whilst delivering unpleasant side-effects. Alternative treatment modalities, such as electroporation, are under development and pancreatic cancer still awaits a “game-changer”.
UR  - https://tcr.amegroups.org/article/view/8766